Press Releases

March 26, 2018
Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis Read More
March 9, 2018
Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference Read More
March 7, 2018
Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results Read More
March 6, 2018
FDA Grants Orphan Drug Designation for Protagonist Therapeutics' PTG-300 for the Treatment of Beta-Thalassemia Read More
March 1, 2018
Protagonist Therapeutics to Participate in the Barclay's Global Healthcare Conference Read More
March 1, 2018
Protagonist to Announce Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018; Year-End Update Call to Follow Read More
January 31, 2018
Protagonist Therapeutics to Participate in the Leerink Partners 7th Annual Global Healthcare Conference Read More
January 4, 2018
Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300 Read More
December 14, 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors Read More
December 14, 2017
Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 Read More
December 4, 2017
Protagonist Therapeutics to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference Read More
November 9, 2017
Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200 Read More
November 6, 2017
Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update Read More
November 1, 2017
Protagonist Therapeutics to Present at the Stifel 2017 Healthcare Conference Read More
October 11, 2017
Protagonist Therapeutics Prices Public Offering of Common Stock Read More
October 11, 2017
Protagonist Therapeutics Announces Proposed Public Offering of Common Stock Read More
September 20, 2017
Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 Read More
September 14, 2017
/C O R R E C T I O N -- Protagonist Therapeutics, Inc./ Read More
September 11, 2017
Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Read More
August 24, 2017
Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment Read More